SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma
Jorien B.E. Janssen(Radboud University Nijmegen), Henk M.W. Verheul(Erasmus MC)
Cited by 0
Related Papers
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
|Angiogenesis|2009|488